Infinity Pharmaceuticals, Inc. I3F.F Stock
Infinity Pharmaceuticals, Inc. Price Chart
Infinity Pharmaceuticals, Inc. I3F.F Financial and Trading Overview
Infinity Pharmaceuticals, Inc. stock price | 0.02 EUR |
Previous Close | 0.15 EUR |
Open | 0.15 EUR |
Bid | 0.15 EUR x 520000 |
Ask | 0.25 EUR x 520000 |
Day's Range | 0.15 - 0.15 EUR |
52 Week Range | 0.09 - 1.68 EUR |
Volume | 1.08K EUR |
Avg. Volume | 19 EUR |
Market Cap | 14.19M EUR |
Beta (5Y Monthly) | 1.359859 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.67 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.29 EUR |
I3F.F Valuation Measures
Enterprise Value | -11887841 EUR |
Trailing P/E | N/A |
Forward P/E | -0.25278687 |
PEG Ratio (5 yr expected) | -0.08 |
Price/Sales (ttm) | 5.31178 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | -4.449 |
Enterprise Value/EBITDA | 0.273 |
Trading Information
Infinity Pharmaceuticals, Inc. Stock Price History
Beta (5Y Monthly) | 1.359859 |
52-Week Change | -77.14% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1.68 EUR |
52 Week Low | 0.09 EUR |
50-Day Moving Average | 0.14 EUR |
200-Day Moving Average | 0.61 EUR |
I3F.F Share Statistics
Avg. Volume (3 month) | 19 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 89.9M |
Float | 81.63M |
Short Ratio | N/A |
% Held by Insiders | 2.15% |
% Held by Institutions | 28.78% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -1644.61% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -53.57% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 2.67M EUR |
Revenue Per Share (ttm) | 0.03 EUR |
Quarterly Revenue Growth (yoy) | 12.09% |
Gross Profit (ttm) | -31381000 EUR |
EBITDA | -43502000 EUR |
Net Income Avi to Common (ttm) | -42978000 EUR |
Diluted EPS (ttm) | -0.43 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 25.74M EUR |
Total Cash Per Share (mrq) | 0.29 EUR |
Total Debt (mrq) | 777K EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 2.512 |
Book Value Per Share (mrq) | -0.317 |
Cash Flow Statement
Operating Cash Flow (ttm) | -41472000 EUR |
Levered Free Cash Flow (ttm) | -24454500 EUR |
Profile of Infinity Pharmaceuticals, Inc.
Country | Germany |
State | MA |
City | Cambridge |
Address | 1100 Massachusetts Avenue |
ZIP | 02138 |
Phone | (617) 453-1000 |
Website | https://www.infi.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 30 |
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.
Q&A For Infinity Pharmaceuticals, Inc. Stock
What is a current I3F.F stock price?
Infinity Pharmaceuticals, Inc. I3F.F stock price today per share is 0.02 EUR.
How to purchase Infinity Pharmaceuticals, Inc. stock?
You can buy I3F.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Infinity Pharmaceuticals, Inc.?
The stock symbol or ticker of Infinity Pharmaceuticals, Inc. is I3F.F.
Which industry does the Infinity Pharmaceuticals, Inc. company belong to?
The Infinity Pharmaceuticals, Inc. industry is Biotechnology.
How many shares does Infinity Pharmaceuticals, Inc. have in circulation?
The max supply of Infinity Pharmaceuticals, Inc. shares is 104.55M.
What is Infinity Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Infinity Pharmaceuticals, Inc. PE Ratio is now.
What was Infinity Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Infinity Pharmaceuticals, Inc. EPS is -0.67 EUR over the trailing 12 months.
Which sector does the Infinity Pharmaceuticals, Inc. company belong to?
The Infinity Pharmaceuticals, Inc. sector is Healthcare.